Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CDH17/anti-CD3 bispecific antibody ARB202

A bispecific antibody directed against both the T-cell surface antigen CD3 and the tumor-associated antigen (TAA) cadherin-17 (CDH17), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CDH17/anti-CD3 bispecific antibody ARB202 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and CDH17 on CDH17-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CDH17-expressing tumor cells, which results in the CTL-mediated cell death of CDH17-expressing tumor cells. CDH17, a cell surface adhesion protein, is overexpressed in a variety of cancer cell types.
Synonym:anti-CDH17/CD3 bispecific T-cell engager ARB202
CDH17 x CD3 bispecific antibody ARB202
Code name:ARB 202
ARB-202
ARB202
Search NCI's Drug Dictionary